Mallinckrodt Baker, Inc. and Rubicon Research Sign Agreement for Performance Excipient Development
8/18/2008 8:49:22 AM
PHILLIPSBURG, N.J.--(BUSINESS WIRE)--Covidien (NYSE: COV, BSX: COV), a leading global provider of healthcare products, today announced that its Mallinckrodt Baker business has entered into a licensing and commercialization agreement with drug development research specialist Rubicon Research. Following the July 2008 launch of its PanExceaTM performance excipient, Mallinckrodt Baker is teaming with Rubicon Research to expand its performance excipient platform. The two companies will develop and launch additional products under the PanExcea brand through 2009.
comments powered by